Exporting Active Pharmaceutical Ingredients to the US — Drug Manufacturers

Active Pharmaceutical Ingredients (APIs) are the biologically active components in finished drug products, forming the core of any therapeutic formulation. For US drug manufacturers, a reliable and compliant API supply chain is essential to meet the stringent demands of the Food and Drug Administration (FDA) and to ensure uninterrupted production of generic and branded medications. The United States is the world’s largest pharmaceutical market, with annual spending exceeding $500 billion, and APIs represent a critical upstream segment of this ecosystem [1]. US drug manufacturers depend on a global network of API suppliers, with a significant share sourced from India and China. However, recent supply chain disruptions, geopolitical tensions, and increased regulatory scrutiny have created a compelling opportunity for Latin American and African suppliers to enter the US market with high-quality, competitively priced APIs. This page provides a comprehensive overview for suppliers and buyers navigating the US API trade landscape.

Product Specifications and Grades Relevant to US Buyers

APIs are manufactured according to strict pharmacopeial standards, primarily the United States Pharmacopeia (USP), as well as the European Pharmacopoeia (Ph. Eur.) for products with global distribution. US drug manufacturers require APIs that meet USP monographs, which define purity, potency, impurity limits, and physical characteristics such as particle size and solubility. APIs are classified by therapeutic category, including anti-infectives (e.g., amoxicillin, azithromycin), cardiovascular agents (e.g., atorvastatin, losartan), central nervous system drugs (e.g., sertraline, quetiapine), and oncology compounds (e.g., imatinib, lenalidomide). Each API must be accompanied by a Drug Master File (DMF) filed with the FDA, which contains detailed manufacturing and quality data. US buyers often specify additional requirements, such as residual solvent limits per ICH Q3C, heavy metal testing per USP <231>, and microbial limits per USP <61> and <62>. For generic drug manufacturers, the API must demonstrate bioequivalence to the reference listed drug, supported by robust stability data and impurity profiles. High-purity APIs (typically >98% by HPLC) are standard, with some niche products requiring >99.5%. The physical form—crystalline or amorphous, anhydrous or hydrated—can significantly affect formulation and bioavailability, making it a key specification in procurement contracts.

LATAM and Africa Supplier Landscape for APIs

Latin America has a well-established pharmaceutical manufacturing base, with countries like Mexico, Brazil, Argentina, and Colombia hosting FDA-inspected facilities. Mexico, in particular, is a major API producer, with over 100 plants registered with the FDA, many specializing in steroids, hormones, and anti-infectives [2]. Brazil’s API production is concentrated in generics, supported by a large domestic market and regulatory alignment with ANVISA, which has mutual recognition agreements with the FDA for certain inspections. Argentina has a strong track record in biotechnology-derived APIs, including insulin and monoclonal antibodies. Chile and Peru are emerging players, focusing on natural product-derived APIs such as alkaloids from local flora. In Africa, South Africa leads API production, with several facilities approved by the FDA and European Medicines Agency, particularly for antiretroviral drugs and tuberculosis treatments. Kenya and Nigeria are developing capacity for basic APIs, supported by local manufacturing initiatives and international donor programs. However, the African API landscape remains nascent compared to LATAM, with challenges in infrastructure, regulatory harmonization, and access to capital. For US buyers, LATAM offers geographic proximity, time zone alignment, and established trade agreements like the USMCA, which reduces tariffs on many pharmaceutical inputs. Suppliers in both regions must demonstrate compliance with current Good Manufacturing Practices (cGMP) as defined by 21 CFR Parts 210 and 211, and undergo regular FDA inspections or audits.

US Buyer Types: Who Buys APIs and How They Procure

US drug manufacturers span a spectrum from large multinational corporations to mid-size generic houses and specialty pharmaceutical companies. Large innovator companies (e.g., Pfizer, Merck, Johnson & Johnson) typically source APIs through long-term contracts with a limited number of approved suppliers, often requiring dedicated manufacturing lines and extensive quality agreements. Generic drug manufacturers (e.g., Teva, Mylan, Sandoz) are price-sensitive but equally quality-conscious, procuring APIs through competitive tenders and multi-year supply agreements. Specialty pharmaceutical firms focusing on niche therapies (e.g., orphan drugs, oncology) require smaller volumes but demand high technical support and regulatory expertise. Contract manufacturing organizations (CMOs) serve as intermediaries, purchasing APIs to produce finished dosage forms for multiple clients. Procurement is driven by the FDA’s Drug Master File system: suppliers must submit a Type II DMF for each API, which is reviewed by the FDA during the drug application process. Buyers typically request samples for analytical testing and bioequivalence studies before qualifying a new supplier. Lead times for qualification can range from 6 to 18 months, depending on the complexity of the API and the buyer’s regulatory history. Price negotiation is informed by the API’s therapeutic value, manufacturing complexity, and competitive landscape; for example, high-volume generic APIs like metformin are priced near cost, while complex oncology APIs command premium margins.

Certifications and Import Requirements for APIs

Importing APIs into the United States requires rigorous compliance with federal regulations administered by the FDA under the Federal Food, Drug, and Cosmetic Act. All API manufacturing facilities must be registered with the FDA and listed in the agency’s database. Each API batch must be accompanied by a Certificate of Analysis (CoA) confirming it meets USP or other applicable specifications. The FDA conducts pre-approval inspections (PAIs) for new API sources and routine surveillance inspections every two to three years. Suppliers must maintain a Quality Management System (QMS) aligned with ICH Q10, covering change control, deviation management, and stability programs. Additionally, the Drug Supply Chain Security Act (DSCSA) imposes traceability requirements for certain prescription drugs, though APIs are currently exempt from full DSCSA serialization, they must still comply with recordkeeping and transaction history provisions. For APIs derived from biological sources, additional regulations under 21 CFR Part 600 apply. Environmental compliance is also required: the National Environmental Policy Act (NEPA) may necessitate an environmental assessment for new drug applications. For imports, the US Customs and Border Protection (CBP) requires proper Harmonized Tariff Schedule (HTS) classification; API HTS codes generally fall under Chapter 29 (Organic Chemicals) or Chapter 30 (Pharmaceutical Products), with duty rates ranging from 0% to 6.5% depending on the specific compound and country of origin [3]. Suppliers in LATAM benefit from duty-free entry under the USMCA for many APIs, while African suppliers may qualify for preferential rates under the African Growth and Opportunity Act (AGOA) if the API is wholly obtained or substantially transformed in a beneficiary country.

Pricing and Lead Time Context

API pricing is highly variable and influenced by raw material costs, synthesis complexity, scale, and regulatory status. For generic APIs with multiple suppliers, prices can be as low as $10–$50 per kilogram for simple molecules like paracetamol, while complex oncology APIs can exceed $10,000 per kilogram. Prices are often quoted on a per-kilogram basis, with discounts for larger volumes (e.g., metric ton orders). Lead times for initial qualification and commercial supply typically range from 6 to 12 months for a new supplier, including DMF submission, sample testing, and FDA inspection scheduling. For established suppliers with an existing DMF, lead times for routine orders are 4–8 weeks, depending on production capacity and logistics. Shipping from LATAM to US ports takes 3–7 days by air freight or 2–4 weeks by ocean freight, with air freight preferred for high-value or temperature-sensitive APIs. African suppliers face longer transit times (2–4 weeks by air, 4–8 weeks by ocean) and higher logistics costs, though recent investments in cold chain infrastructure are improving reliability. Payment terms are typically net 30 to net 60 for approved suppliers, with letters of credit often required for new relationships. Currency risk is managed via USD-denominated contracts. Overall, US drug manufacturers are willing to pay a premium for supply security and regulatory compliance, making LATAM and Africa competitive alternatives to Asian sources.

How Coppermont Connects Suppliers to Buyers

Coppermont bridges the gap between LATAM and African API suppliers and US drug manufacturers through a structured advisory and matchmaking process. We begin by assessing the supplier’s technical capabilities, regulatory status, and production capacity against the specific needs of US buyers. Our team assists suppliers in preparing FDA-compliant DMFs, conducting gap analyses against cGMP requirements, and navigating the FDA inspection process. For buyers, we provide vetted supplier profiles, facilitate sample exchanges, and support quality agreement negotiations. Our deep understanding of US pharmaceutical procurement cycles—including the Drug Master File system, bioequivalence studies, and supply chain security—enables us to accelerate supplier qualification timelines. Whether you are a supplier seeking to expand into the US market or a drug manufacturer looking to diversify your API sourcing, Coppermont offers tailored solutions to reduce risk, improve cost efficiency, and ensure regulatory compliance. Contact us today to begin the conversation.

Supplier CTA: Ready to supply APIs to the US market? Let Coppermont guide you through FDA compliance and buyer qualification.

Buyer CTA: Looking for reliable API sources from LATAM or Africa? Connect with our vetted suppliers and secure your supply chain.